CN107135645A - 用于在伤口愈合中使用的植物提取物和化合物 - Google Patents
用于在伤口愈合中使用的植物提取物和化合物 Download PDFInfo
- Publication number
- CN107135645A CN107135645A CN201580073703.XA CN201580073703A CN107135645A CN 107135645 A CN107135645 A CN 107135645A CN 201580073703 A CN201580073703 A CN 201580073703A CN 107135645 A CN107135645 A CN 107135645A
- Authority
- CN
- China
- Prior art keywords
- tanshinone
- salvia
- plant extracts
- species
- cyp11b1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000419 plant extract Substances 0.000 title claims abstract description 22
- 150000001875 compounds Chemical class 0.000 title description 23
- 230000029663 wound healing Effects 0.000 title description 12
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical class C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 claims abstract description 146
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 64
- 206010052428 Wound Diseases 0.000 claims abstract description 61
- 235000017276 Salvia Nutrition 0.000 claims abstract description 46
- 229930183118 Tanshinone Natural products 0.000 claims abstract description 44
- 230000001684 chronic effect Effects 0.000 claims abstract description 33
- 241000894007 species Species 0.000 claims abstract description 26
- HARGZZNYNSYSGJ-UHFFFAOYSA-N 1,2 dihydrotanshinquinone Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)CO1 HARGZZNYNSYSGJ-UHFFFAOYSA-N 0.000 claims abstract description 25
- -1 tanshinone compound Chemical class 0.000 claims abstract description 25
- HARGZZNYNSYSGJ-JTQLQIEISA-N Dihydrotanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2[C@@H](C)CO1 HARGZZNYNSYSGJ-JTQLQIEISA-N 0.000 claims abstract description 24
- KXNYCALHDXGJSF-UHFFFAOYSA-N dihydroisotanshinone I Natural products CC1=CC=CC2=C(C(C=3OCC(C=3C3=O)C)=O)C3=CC=C21 KXNYCALHDXGJSF-UHFFFAOYSA-N 0.000 claims abstract description 19
- 230000001629 suppression Effects 0.000 claims abstract description 18
- 208000014311 Cushing syndrome Diseases 0.000 claims abstract description 10
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims abstract description 10
- 241001072909 Salvia Species 0.000 claims abstract 11
- 239000000284 extract Substances 0.000 claims description 52
- 102100024332 Cytochrome P450 11B1, mitochondrial Human genes 0.000 claims description 47
- 108010049356 Steroid 11-beta-Hydroxylase Proteins 0.000 claims description 47
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 claims description 16
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 208000025865 Ulcer Diseases 0.000 claims description 4
- 231100000397 ulcer Toxicity 0.000 claims description 4
- 239000012876 carrier material Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 208000010266 Aggressive Periodontitis Diseases 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 201000006727 periodontosis Diseases 0.000 claims description 2
- 239000000606 toothpaste Substances 0.000 claims description 2
- 229940034610 toothpaste Drugs 0.000 claims description 2
- 210000003462 vein Anatomy 0.000 claims description 2
- 206010063562 Radiation skin injury Diseases 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract description 30
- 229960000890 hydrocortisone Drugs 0.000 abstract description 15
- 240000007164 Salvia officinalis Species 0.000 description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- 210000003491 skin Anatomy 0.000 description 24
- 239000000243 solution Substances 0.000 description 21
- 235000005412 red sage Nutrition 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 14
- 235000007154 Salvia chinensis Nutrition 0.000 description 13
- 235000005794 Salvia japonica Nutrition 0.000 description 13
- 244000143590 Salvia chinensis Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 208000004210 Pressure Ulcer Diseases 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 150000002576 ketones Chemical class 0.000 description 6
- 206010011985 Decubitus ulcer Diseases 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000011505 plaster Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010056340 Diabetic ulcer Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000304195 Salvia miltiorrhiza Species 0.000 description 3
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000002020 sage Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 2
- ONUSCCKLNWURMA-UHFFFAOYSA-N 3,8-dimethylnaphtho[2,1-g][1]benzofuran-4,5-dione Chemical compound O=C1C(=O)C2=CC=C3C(C)=CC=CC3=C2C2=C1C(C)=CO2 ONUSCCKLNWURMA-UHFFFAOYSA-N 0.000 description 2
- XYKZSUXWBGUGQV-UHFFFAOYSA-N 4,8-dimethylnaphtho[2,1-f][1]benzofuran-7,11-dione Chemical compound CC1=CC=CC2=C(C(C=3OC=C(C=3C3=O)C)=O)C3=CC=C21 XYKZSUXWBGUGQV-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- FEFAIBOZOKSLJR-UHFFFAOYSA-N Miltirone Chemical compound C1CCC(C)(C)C=2C1=C1C(=O)C(=O)C(C(C)C)=CC1=CC=2 FEFAIBOZOKSLJR-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 235000001499 Salvia glutinosa Nutrition 0.000 description 2
- 240000006476 Salvia glutinosa Species 0.000 description 2
- 235000002912 Salvia officinalis Nutrition 0.000 description 2
- 240000008125 Salvia polystachya Species 0.000 description 2
- 235000006108 Salvia polystachya Nutrition 0.000 description 2
- 235000002911 Salvia sclarea Nutrition 0.000 description 2
- 244000182022 Salvia sclarea Species 0.000 description 2
- 208000000558 Varicose Ulcer Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 240000001735 chia Species 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000001691 salvia sclarea Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- HWOCQHAIRMKGII-UHFFFAOYSA-N 1-phenyl-1h-tetrazol-1-ium;bromide Chemical compound [Br-].N1=NN[N+](C=2C=CC=CC=2)=C1 HWOCQHAIRMKGII-UHFFFAOYSA-N 0.000 description 1
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 description 1
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-UHFFFAOYSA-N 11-deoxy-17-hydroxy-corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 WHBHBVVOGNECLV-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- UWSONZCNXUSTKW-UHFFFAOYSA-N 4,5-Dimethylthiazole Chemical compound CC=1N=CSC=1C UWSONZCNXUSTKW-UHFFFAOYSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 241000700112 Chinchilla Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241001268392 Dalla Species 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000246500 Gentianella aspera Species 0.000 description 1
- 101100219201 Homo sapiens CYP11B1 gene Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000005410 Mexican sage Nutrition 0.000 description 1
- 241000699703 Microtus pennsylvanicus Species 0.000 description 1
- 241000887044 Myripnois Species 0.000 description 1
- 241000171154 Nematus <genus> Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 235000002302 Salvia apiana Nutrition 0.000 description 1
- 235000001496 Salvia argentea Nutrition 0.000 description 1
- 241000227765 Salvia argentea Species 0.000 description 1
- 235000006103 Salvia arizonica Nutrition 0.000 description 1
- 244000159860 Salvia arizonica Species 0.000 description 1
- 235000002300 Salvia azurea Nutrition 0.000 description 1
- 244000126818 Salvia azurea Species 0.000 description 1
- 235000006863 Salvia carnosa Nutrition 0.000 description 1
- 244000260602 Salvia carnosa Species 0.000 description 1
- 235000006274 Salvia clevelandii Nutrition 0.000 description 1
- 244000113863 Salvia clevelandii Species 0.000 description 1
- 235000012223 Salvia coccinea Nutrition 0.000 description 1
- 244000178134 Salvia coccinea Species 0.000 description 1
- 235000011771 Salvia divinorum Nutrition 0.000 description 1
- 241001136613 Salvia divinorum Species 0.000 description 1
- 235000016274 Salvia dorrii Nutrition 0.000 description 1
- 241001226049 Salvia dorrii Species 0.000 description 1
- 239000009724 Salvia extract Substances 0.000 description 1
- 235000006269 Salvia farinacea Nutrition 0.000 description 1
- 244000113842 Salvia farinacea Species 0.000 description 1
- 241000355338 Salvia forreri Species 0.000 description 1
- 235000010807 Salvia fulgens Nutrition 0.000 description 1
- 241000862354 Salvia fulgens Species 0.000 description 1
- 235000015356 Salvia funerea Nutrition 0.000 description 1
- 244000048669 Salvia funerea Species 0.000 description 1
- 235000006290 Salvia greggii Nutrition 0.000 description 1
- 241000122625 Salvia greggii Species 0.000 description 1
- 235000004062 Salvia guaranitica Nutrition 0.000 description 1
- 241001184577 Salvia guaranitica Species 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- 235000000084 Salvia leucantha Nutrition 0.000 description 1
- 241000261355 Salvia leucantha Species 0.000 description 1
- 235000002299 Salvia leucophylla Nutrition 0.000 description 1
- 241000862239 Salvia leucophylla Species 0.000 description 1
- 241001643689 Salvia longistyla Species 0.000 description 1
- 235000006141 Salvia lyrata Nutrition 0.000 description 1
- 241000122632 Salvia lyrata Species 0.000 description 1
- 244000120680 Salvia mexicana Species 0.000 description 1
- 235000002887 Salvia mexicana Nutrition 0.000 description 1
- 241001226044 Salvia pachyphylla Species 0.000 description 1
- 235000000524 Salvia patens Nutrition 0.000 description 1
- 241000862254 Salvia patens Species 0.000 description 1
- 235000001503 Salvia pratensis Nutrition 0.000 description 1
- 244000251853 Salvia pratensis Species 0.000 description 1
- 235000006104 Salvia roemeriana Nutrition 0.000 description 1
- 241000122595 Salvia roemeriana Species 0.000 description 1
- 235000006107 Salvia spathacea Nutrition 0.000 description 1
- 241000122590 Salvia spathacea Species 0.000 description 1
- 235000017668 Salvia splendens Nutrition 0.000 description 1
- 240000001438 Salvia splendens Species 0.000 description 1
- 235000001502 Salvia verticillata Nutrition 0.000 description 1
- 241000227806 Salvia verticillata Species 0.000 description 1
- 235000001486 Salvia viridis Nutrition 0.000 description 1
- 244000258070 Salvia viridis Species 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000001194 anti-hemostatic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002710 external beam radiation therapy Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229930195208 isotanshinone Natural products 0.000 description 1
- QHGPIJMPUOVBOL-UHFFFAOYSA-N isotanshinone IIA Natural products O=C1C2=CC=C(C(CCC3)(C)C)C3=C2C(=O)C2=C1C(C)=CO2 QHGPIJMPUOVBOL-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000037309 reepithelialization Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- PRYXPGFZVGZNBL-ADLFWFRXSA-N salviol Chemical compound CC(C)c1cc2CC[C@H]3C(C)(C)C[C@H](O)C[C@]3(C)c2cc1O PRYXPGFZVGZNBL-ADLFWFRXSA-N 0.000 description 1
- AJSGWTLZEUBGFV-UHFFFAOYSA-N salviol Natural products CC(C)c1cc2CCC3C(CC(O)CC3(C)C)c2cc1O AJSGWTLZEUBGFV-UHFFFAOYSA-N 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000010129 solution processing Methods 0.000 description 1
- 239000001590 sorbitan monolaureate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000000365 steroidogenetic effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6955—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a plaster, a bandage, a dressing or a patch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Birds (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1421479.5A GB201421479D0 (en) | 2014-12-03 | 2014-12-03 | A plant extract and compounds for use in wound healing |
| GB1421479.5 | 2014-12-03 | ||
| PCT/GB2015/000312 WO2016087810A1 (en) | 2014-12-03 | 2015-11-30 | A plant extract and compounds for use in wound healing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107135645A true CN107135645A (zh) | 2017-09-05 |
Family
ID=52349874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580073703.XA Pending CN107135645A (zh) | 2014-12-03 | 2015-11-30 | 用于在伤口愈合中使用的植物提取物和化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20180228858A1 (enExample) |
| EP (1) | EP3226879A1 (enExample) |
| JP (1) | JP6829691B2 (enExample) |
| CN (1) | CN107135645A (enExample) |
| GB (2) | GB201421479D0 (enExample) |
| WO (1) | WO2016087810A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110251716A (zh) * | 2019-04-22 | 2019-09-20 | 张贤慧 | 一种伤口护理用凝胶敷料及其制备方法 |
| TWI750705B (zh) * | 2020-06-19 | 2021-12-21 | 慈濟學校財團法人慈濟大學 | 預防及/或治療壓力誘發疾病之方法 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102687221B1 (ko) * | 2016-12-05 | 2024-07-22 | 주식회사 엘지생활건강 | 디하이드로탄시논 ⅰ을 포함하는 구강질환 예방 또는 치료용 조성물 |
| US20210393585A1 (en) * | 2020-06-19 | 2021-12-23 | Tzu Chi University | Method for preventing and/or treating a stress-induced disease |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1056285C (zh) * | 1993-02-10 | 2000-09-13 | 伊塞哈根药材经营股份有限公司 | 含有鼠尾草花提取物的药物 |
| CN101119726A (zh) * | 2005-02-16 | 2008-02-06 | Md白奥阿尔法有限公司 | 用于治疗或预防涉及肥胖、糖尿病、代谢综合症、神经变性疾病和线粒体功能障碍疾病的疾病的药物组合物 |
| CN101411745A (zh) * | 2007-10-15 | 2009-04-22 | 博仲盛景医药技术（北京）有限公司 | 一种抗菌丹参酮提取物、其制备方法、用途及其产品 |
| CN101642486A (zh) * | 2009-08-28 | 2010-02-10 | 湖南省中医药研究院 | 一种促进创伤愈合的中药组合物及其制备方法 |
| JP2010106001A (ja) * | 2008-10-31 | 2010-05-13 | Theravalues Corp | Ｐｐａｒ活性化剤 |
| CN103705616A (zh) * | 2014-01-02 | 2014-04-09 | 魏春战 | 一种祛腐生肌膏的配方 |
| CN103830175A (zh) * | 2012-11-26 | 2014-06-04 | 青岛百草汇中草药研究所 | 含有丹参酮的乳剂及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59163319A (ja) * | 1983-03-07 | 1984-09-14 | Sawai Seiyaku Kk | 抗真菌剤 |
| JPH0830077B2 (ja) * | 1987-04-24 | 1996-03-27 | 晟 八木 | 虚血性疾患治療剤 |
| KR100861186B1 (ko) * | 2001-03-26 | 2008-09-30 | 주식회사 엘지생활건강 | 크립토탄시논을 함유하는 여드름 예방 및 치료용 화장료 |
| EP1706108A4 (en) * | 2003-12-30 | 2009-08-12 | Md Bioalpha Co Ltd | TREATMENT OF FAT AND METABOLIC SYNDROME WITH TRANSHINONE DERIVATIVES FOR INCREASING METABOLISM ACTIVITY |
| KR100725839B1 (ko) * | 2005-10-06 | 2007-12-11 | 일성신약주식회사 | 단삼으로부터 분리된 탄시논류의 화합물을 함유하는인지기능 장애의 예방 및 치료용 조성물 |
| CN102579650B (zh) * | 2011-03-10 | 2014-02-26 | 成都中医药大学 | 一种预防或/和治疗压疮的药物组合物及其制备方法和用途 |
| CN102727581B (zh) * | 2011-04-11 | 2016-02-10 | 苏州瑞美科生物技术有限公司 | 一种对伤口具有修复作用的药物组合物 |
| CN103356844B (zh) * | 2012-03-28 | 2015-12-16 | 苏州瑞美科生物技术有限公司 | 一种低聚壳聚糖复方制剂及其在制备治疗皮肤疾病的药物中应用 |
| CN102824599B (zh) * | 2012-08-07 | 2013-12-25 | 孟庆德 | 一种治疗糖尿病引起的各种皮肤溃烂的中药酊剂 |
| CN102988370A (zh) * | 2012-11-23 | 2013-03-27 | 广东省中医院 | 丹参酮i在制备治疗银屑病药物中的应用 |
| CN103040956A (zh) * | 2013-01-18 | 2013-04-17 | 江其生 | 一种能预防和治疗皮肤放射损伤的中药组合物 |
| CN103230493B (zh) * | 2013-04-15 | 2015-04-22 | 杨少辉 | 一种治疗创口不愈的中药组合物 |
-
2014
- 2014-12-03 GB GBGB1421479.5A patent/GB201421479D0/en not_active Ceased
-
2015
- 2015-11-30 WO PCT/GB2015/000312 patent/WO2016087810A1/en not_active Ceased
- 2015-11-30 CN CN201580073703.XA patent/CN107135645A/zh active Pending
- 2015-11-30 US US15/533,009 patent/US20180228858A1/en not_active Abandoned
- 2015-11-30 EP EP15807964.0A patent/EP3226879A1/en not_active Withdrawn
- 2015-11-30 JP JP2017548347A patent/JP6829691B2/ja not_active Expired - Fee Related
- 2015-12-01 GB GB1521166.7A patent/GB2538580B/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1056285C (zh) * | 1993-02-10 | 2000-09-13 | 伊塞哈根药材经营股份有限公司 | 含有鼠尾草花提取物的药物 |
| CN101119726A (zh) * | 2005-02-16 | 2008-02-06 | Md白奥阿尔法有限公司 | 用于治疗或预防涉及肥胖、糖尿病、代谢综合症、神经变性疾病和线粒体功能障碍疾病的疾病的药物组合物 |
| CN101411745A (zh) * | 2007-10-15 | 2009-04-22 | 博仲盛景医药技术（北京）有限公司 | 一种抗菌丹参酮提取物、其制备方法、用途及其产品 |
| JP2010106001A (ja) * | 2008-10-31 | 2010-05-13 | Theravalues Corp | Ｐｐａｒ活性化剤 |
| CN101642486A (zh) * | 2009-08-28 | 2010-02-10 | 湖南省中医药研究院 | 一种促进创伤愈合的中药组合物及其制备方法 |
| CN103830175A (zh) * | 2012-11-26 | 2014-06-04 | 青岛百草汇中草药研究所 | 含有丹参酮的乳剂及其制备方法 |
| CN103705616A (zh) * | 2014-01-02 | 2014-04-09 | 魏春战 | 一种祛腐生肌膏的配方 |
Non-Patent Citations (11)
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110251716A (zh) * | 2019-04-22 | 2019-09-20 | 张贤慧 | 一种伤口护理用凝胶敷料及其制备方法 |
| CN110251716B (zh) * | 2019-04-22 | 2020-12-18 | 张贤慧 | 一种伤口护理用凝胶敷料及其制备方法 |
| TWI750705B (zh) * | 2020-06-19 | 2021-12-21 | 慈濟學校財團法人慈濟大學 | 預防及/或治療壓力誘發疾病之方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2538580B (en) | 2019-07-24 |
| JP6829691B2 (ja) | 2021-02-10 |
| GB201521166D0 (en) | 2016-01-13 |
| GB2538580A (en) | 2016-11-23 |
| US20180228858A1 (en) | 2018-08-16 |
| JP2017537163A (ja) | 2017-12-14 |
| WO2016087810A1 (en) | 2016-06-09 |
| GB201421479D0 (en) | 2015-01-14 |
| EP3226879A1 (en) | 2017-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5970148B2 (ja) | チロシナーゼ活性阻害剤、メラニン産生抑制剤、及びＳＣＦｍＲＮＡ発現抑制剤 | |
| KR101716680B1 (ko) | 자운고 발효 오일 및 이의 제조방법 | |
| KR20090055309A (ko) | 피부미백 및 주름개선용 피부외용 화장료 조성물 | |
| CN107135645A (zh) | 用于在伤口愈合中使用的植物提取物和化合物 | |
| FR3075642A1 (fr) | Extrait de fleurs de kapokier et compositions cosmetiques, pharmaceutiques ou dermatologiques le comprenant | |
| WO2014148711A1 (ko) | 식물성 소재 추출물 및 그 발효 물질에 의한 화장품 제조를 위한 조성물 및 그 제조 방법 | |
| JP7728774B2 (ja) | ヘチマ根抽出物を含む組成物 | |
| KR20190051711A (ko) | 자외선에 의한 피부염증 억제용 항염증 조성물 및 이의 제조 방법 | |
| KR100971655B1 (ko) | 항산화, 항염 및 항주름 효과를 가지는 화장료 조성물 | |
| KR102528199B1 (ko) | 탈모방지 및 발모 촉진용 조성물 | |
| KR101202393B1 (ko) | 자연상태의 생허브를 이용한 허브 추출 조성물, 그 제조방법 및, 이를 이용한 아토피성 피부염 완화를 위한 화장료 조성물. | |
| KR100416400B1 (ko) | 천화분 추출물의 제조방법 및 이를 함유하는 피부 미백용외용제 조성물 | |
| KR102079090B1 (ko) | 적하수오 줄기 추출물을 함유하는 기능성 화장품 조성물 | |
| JP2003504388A (ja) | 化粧品または皮膚薬学的組成物における少なくとも１つのＬａｎｎｅａ属植物抽出物の使用 | |
| EP4281095A1 (fr) | Extrait de parties aeriennes de basilic sacre et compositions cosmetiques, ou dermatologiques le comprenant | |
| KR101190201B1 (ko) | 소나무 뿌리 추출물을 함유하는 화장료 조성물 | |
| KR20170047515A (ko) | 그라비올라 항균 추출물을 함유하는 피부 활력 증진용 화장료 조성물 및 그 제조방법 | |
| KR102685167B1 (ko) | 소나무, 마누카, 수국, 은행나무, 구아바 및 서양머위의 복합 천연물 추출물을 유효성분으로 함유하는 항산화, 피부 탄력 증진 및 피부 진정용 화장료 조성물 | |
| CN112402299A (zh) | 一种具有抗氧化作用的山茶油修复霜的制备方法 | |
| CN116785375B (zh) | 一种天然植物提取物的制备方法及其在制备具有美白作用的产品中的应用 | |
| JP6561135B2 (ja) | 狼毒抽出物またはその分画物を含む、傷を治療するための組成物、及び個体の傷を治療する方法 | |
| KR102670411B1 (ko) | 복합추출물 또는 복합 발효추출물을 유효성분으로 포함하는 화장료 조성물 및 그의 제조방법 | |
| KR102785965B1 (ko) | 쌀겨 추출물, 무화과 추출물, 알바수련 꽃 추출물 및 유자 추출물을 포함하는 피부 미백용 화장료 조성물 | |
| US10953066B2 (en) | Compositions for the treatment of chronic ulcers | |
| KR101278071B1 (ko) | 거제수 나무 추출물을 함유하는 화장료 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170905 |